Detalhe da pesquisa
1.
[Salivary gland cancer: new therapeutic approaches]. / Cancers des glandes salivaires : nouvelles approches thérapeutiques.
Rev Med Suisse
; 19(827): 958-963, 2023 May 17.
Artigo
em Francês
| MEDLINE | ID: mdl-37195109
2.
[Oncology: what's new in 2022]. / Oncologie : ce qui a changé en 2022.
Rev Med Suisse
; 19(N° 809-10): 52-57, 2023 Jan 18.
Artigo
em Francês
| MEDLINE | ID: mdl-36660838
3.
[2021 Oncology update]. / Oncologie.
Rev Med Suisse
; 18(767): 182-186, 2022 Feb 02.
Artigo
em Francês
| MEDLINE | ID: mdl-35107893
4.
[Anaplastic thyroid carcinoma : new therapeutic approaches]. / Carcinome anaplasique de la thyroïde : nouvelles approches thérapeutiques.
Rev Med Suisse
; 17(739): 962-966, 2021 May 19.
Artigo
em Francês
| MEDLINE | ID: mdl-34009754
5.
[2020 oncology update]. / Oncologie.
Rev Med Suisse
; 17(723): 201-205, 2021 Jan 27.
Artigo
em Francês
| MEDLINE | ID: mdl-33507661
6.
18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.
Eur J Nucl Med Mol Imaging
; 46(9): 1859-1868, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31214790
7.
Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma.
Int J Mol Sci
; 20(21)2019 Oct 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31671550
8.
[Head and neck cancer : promising results of immunotherapy]. / Cancers de la sphère ORL : l'immunothérapie donne de la voix !
Rev Med Suisse
; 13(563): 1029-1031, 2017 May 17.
Artigo
em Francês
| MEDLINE | ID: mdl-28636292
9.
A pharmacist-led interprofessional medication adherence program improved adherence to oral anticancer therapies: The OpTAT randomized controlled trial.
PLoS One
; 19(6): e0304573, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38848380
10.
Papillary Thyroid Carcinoma with Desmoid-Type Fibromatosis: Review of Published Cases.
Cancers (Basel)
; 13(17)2021 Sep 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34503292
11.
Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data.
JMIR Res Protoc
; 10(6): e30090, 2021 Jun 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34185020
12.
Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Clin Cancer Res
; 26(24): 6429-6436, 2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32994295
13.
Cisplatin Eligibility Issues and Alternative Regimens in Locoregionally Advanced Head and Neck Cancer: Recommendations for Clinical Practice.
Front Oncol
; 9: 464, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31245288
14.
Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program.
J Cancer
; 9(2): 250-255, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29344270
15.
Inappropriate Grading of Adverse Events in Cancer Clinical Trials-Reply.
JAMA Oncol
; 5(2): 269-270, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30543369
16.
Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group.
JAMA Oncol
; 4(7): 1003-1006, 2018 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29800044